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by assessing patient preferences for non-health outcomes, such
as interactions with the health care provider. Consideration of
non-health outcomes will be important to include in future
evaluations of maternal health services.
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OBJECTIVE: To determine current usage of palivizumab pro-
phylaxis, the compliance patterns, hospitalization rates and out-
comes in children at high-risk of respiratory syncytial virus
(RSV) infection through the development of a Canadian Regis-
try Database (CARESS). METHODS: A prospective, longitudi-
nal, observational, follow-up study of Canadian infants who
received palivizumab prophylaxis in the 2006/2007 RSV season.
Neonatal and demographic data were collected from the parent/
caregiver upon enrollment. Parents/caregivers were contacted
monthly (at next injection or by telephone) by site nurses for
data on palivizumab utilization and compliance, and outcomes
related to any respiratory tract events. RESULTS: Information
was collected on 1224 infants who received at least one injec-
tion of palivizumab and who ranged in age from 2 days to 34
months (mean = 5.17 months). Participating children were typi-
cally male (57.4%) and Caucasian (72.2%). Gestational age
was 31.5  4.3 weeks. 914 infants (74.7%) received palivi-
zumab primarily for prematurity (35 completed weeks gesta-
tional age), 119 (9.7%) had bronchopulmonary dysplasia and
required supportive oxygen therapy, 119 (9.7%) had congenital
heart disease and 72 (5.9%) were prophylaxed for other risk
factors. A total of 76.9% of subjects received at least 4 injec-
tions of palivizumab, with a total of 5355 doses, overall.
The majority of injections were administered within the recom-
mended monthly time intervals (73.5%). There was a 5.1%
hospitalization rate for respiratory tract events (e.g., bronchioli-
tis or pneumonia). The RSV positive hospitalization rate was
1.2% (proven RSV). Hospitalization rates for respiratory tract
events were highest in those with bronchopulmonary dysplasia
(12.8%, p < 0.001), and in those of Hispanic (15.4%) or
Aboriginal descent (13.6%) (p = 0.051). CONCLUSION: Com-
pliance with the course of palivizumab therapy was very good.
The RSV hospitalization rate observed in the 2006/2007
CARESS season was lower than that previously documented in
the scientiﬁc literature.
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OBJECTIVE: Patient satisfaction (PS) is an important outcome
of erectile dysfunction (ED) treatment. One of the questionnaires
used for PS assessment is EDITS (Erectile Dysfunction Inventory
of Treatment Satisfaction). Besides PDE-5 inhibitors (sildenaﬁl,
tadalaﬁl, vardenaﬁl) various food supplements (FS), with limited
efﬁcacy evidence, are widely used in Czech Republic as they do
not require medical prescription and are advertised directly to
customers. This study represents a ﬁrst direct comparison of
patient’s satisfaction with Viagra (sildenaﬁl) vs. food supple-
ments in erectile dysfunction and a cost-effectiveness analysis
(CEA) for both treatments. METHODS: A retrospective analysis
covering 612 patients who used either sildenaﬁl or FS was per-
formed in 27 urology outpatients clinics using the EDITS ques-
tionnaire. Eligible men had to be between 40 and 75 years old,
using either sildenaﬁl or FS during the past 4 months in the
recommended dosing. Patients who consulted an urologist pri-
marily because of ED or an acute event were excluded to avoid
bias. Data about strength, pack size and number of monthly
purchased packs were also collected for the CE calculation.
RESULTS: Patients using sildenaﬁl showed higher overall satis-
faction scores (78.4 vs. 44.5 p < 0.001) and superiority in all
questions directly connected to efﬁcacy. Mean monthly acquisi-
tion costs for sildenaﬁl were €61, for FS €32. CE was calculated
as a fraction of monthly costs and satisﬁed patients (i.e. patients
with a score of 50). These costs were €65/satisﬁed in sildenaﬁl
vs. €75/satisﬁed in FS groups. If incremental ratios of individual
sildenaﬁl strengths were compared to FS, the 25 mg was domi-
nant; 50 and 100 mg showed ICER/months of €0.75 and €1.25
respectively. CONCLUSION: Sildenaﬁl showed signiﬁcant
higher satisfaction rates in patients with ED compared to FS.
Although monthly acquisition costs for sildenaﬁl are almost
double compared to FS, CE calculations are beneﬁcial for the
sildenaﬁl group.
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OBJECTIVE: To examine rates of potentially inappropriate pre-
scribing in a population dually eligible for Medicare and Medic-
aid using the new 2003 Fick update. The 2003 Fick update
revises the previous 1997 Beers list—an internationally recog-
nized list of drugs identiﬁed as potentially inappropriate to
prescribe to seniors due to an elevated risk of adverse effects,
developed by Dr. Mark Beers. METHODS: Descriptive analyses
(population parameter assessments) were conducted on the 2003
Medicaid ﬁles for elderly enrollees dually eligible for Medicare
and Medicaid. Inappropriate drugs independent of diagnosis as
identiﬁed by the 2003 Fick update were analyzed. RESULTS:
Our enrollee population was comprised of 5,412,678 enrollees
(71% female, 41% age 65–74, 66% Caucasian) with 24%
receiving an inappropriate drug per the 1997 Beers list; 34% per
the 2003 Fick update. Across all census regions, Hispanic enroll-
ees received the highest percentage of inappropriate drugs per the
2003 Fick update. Of enrollees with drug use (3,879,039 enroll-
ees), 34% received an inappropriate drug per the 1997 Beers list;
47% per the 2003 Fick update. Hispanics had the highest per-
centage of drug recipients receiving an inappropriate drug in the
Northeast region per the 2003 Fick update. Within therapeutic
category, the number of inappropriate genitourinary products
dispensed to total genitourinary products ranked the highest at
20% (the drug Nitrofurantoin prescribed most) per the 2003
Fick update. CONCLUSION: Based on the 2003 Fick update,
47% of elderly dually eligible Medicare and Medicaid drug
recipients received inappropriate drugs. However, such use may
be justiﬁed in some circumstances when the beneﬁts outweigh the
risks for an individual patient. Our ﬁndings provide evidence that
the potential use of inappropriate drugs in Hispanics should be
considered separately from other ethnicity groups. By comparing
A252 Abstracts
